Skip Nav Destination
Issues
15 February 2010
-
Cover Image
Cover Image
![issue cover]()
Close ModalExpression of the miR-34 family was found to be frequently reduced in human epithelial ovarian cancer, particularly so in tumors with p53 mutations. The figure shows miR-34a expression (dark blue) in ovarian serous adenocarcinoma as determined by in situ hybridization with locked nucleic acid–modified probes. Immunohistochemistry in serial sections revealed significant inverse correlation between miR-34a and its target MET, an oncogene commonly overexpressed in advanced stages of cancer. For details, see the article by Corney and colleagues on page 1119 of this issue.
- PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
CCR Translations
Molecular Pathways
Perspectives
Human Cancer Biology
High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma
Jane Carr-Wilkinson; Kieran O'Toole; Katrina M. Wood; Christine C. Challen; Angela G. Baker; Julian R. Board; Laura Evans; Michael Cole; Nai-Kong V. Cheung; Joachim Boos; Gabriele Köhler; Ivo Leuschner; Andrew D.J. Pearson; John Lunec; Deborah A. Tweddle
Cancer Therapy: Preclinical
Dasatinib Inhibits the Growth of Molecularly Heterogeneous Myeloid Leukemias
Bella S. Guerrouahen; Muneyoshi Futami; Christos Vaklavas; Jukka Kanerva; Zakary L. Whichard; Kenechi Nwawka; Elisabeth G. Blanchard; Francis Y. Lee; Lisa J. Robinson; Robert Arceci; Steven M. Kornblau; Eric Wieder; Yvon E. Cayre; Seth J. Corey
AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer
D. Mark Hickinson; Teresa Klinowska; Georgina Speake; John Vincent; Cath Trigwell; Judith Anderton; Sarah Beck; Gayle Marshall; Sara Davenport; Rowena Callis; Elizabeth Mills; Konstantina Grosios; Paul Smith; Bernard Barlaam; Robert W. Wilkinson; Donald Ogilvie
Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells
Zhaojing Zhong; Kyla Driscoll Carroll; Desiree Policarpio; Carla Osborn; Michael Gregory; Rajiv Bassi; Xenia Jimenez; Marie Prewett; Gregory Liebisch; Kris Persaud; Douglas Burtrum; Su Wang; David Surguladze; Stanley Ng; Heather Griffith; Paul Balderes; Jacqueline Doody; Jonathan D. Schwartz; Hagop Youssoufian; Eric K. Rowinsky; Dale L. Ludwig; Larry Witte; Zhenping Zhu; Yan Wu
Imaging, Diagnosis, Prognosis
MutS Homologue 2 and the Long-term Benefit of Adjuvant Chemotherapy in Lung Cancer
for the International Adjuvant Lung Trial-Bio investigators; Nermine S. Kamal; Jean-Charles Soria; Jean Mendiboure; David Planchard; Ken A. Olaussen; Vanessa Rousseau; Helmut Popper; Robert Pirker; Pascale Bertrand; Ariane Dunant; Thierry Le Chevalier; Martin Filipits; Pierre Fouret
Tobacco Use in Human Papillomavirus–Positive Advanced Oropharynx Cancer Patients Related to Increased Risk of Distant Metastases and Tumor Recurrence
Jessica H. Maxwell; Bhavna Kumar; Felix Y. Feng; Francis P. Worden; Julia S. Lee; Avraham Eisbruch; Gregory T. Wolf; Mark E. Prince; Jeffrey S. Moyer; Theodoros N. Teknos; Douglas B. Chepeha; Jonathan B. McHugh; Susan G. Urba; Jay Stoerker; Heather M. Walline; David M. Kurnit; Kitrina G. Cordell; Samantha J. Davis; Preston D. Ward; Carol R. Bradford; Thomas E. Carey
Low Levels of Phosphorylated Epidermal Growth Factor Receptor in Nonmalignant and Malignant Prostate Tissue Predict Favorable Outcome in Prostate Cancer Patients
Peter Hammarsten; Amar Karalija; Andreas Josefsson; Stina Häggström Rudolfsson; Pernilla Wikström; Lars Egevad; Torvald Granfors; Pär Stattin; Anders Bergh
Cancer Therapy: Clinical
A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
D. Ross Camidge; Roy S. Herbst; Michael S. Gordon; S. Gail Eckhardt; Razelle Kurzrock; Blythe Durbin; Josephine Ing; Tanyifor M. Tohnya; Jason Sager; Avi Ashkenazi; Gordon Bray; David Mendelson
Tipifarnib Plus Tamoxifen in Tamoxifen-Resistant Metastatic Breast Cancer: A Negative Phase II and Screening of Potential Therapeutic Markers by Proteomic Analysis
Florence Dalenc; Sophie F. Doisneau-Sixou; Ben C. Allal; Sabrina Marsili; Valérie Lauwers-Cances; Karima Chaoui; Odile Schiltz; Bernard Monsarrat; Thomas Filleron; Nicole Renée; Emilie Malissein; Elise Meunier; Gilles Favre; Henri Roché
The Predictive Value of HLA Class I Tumor Cell Expression and Presence of Intratumoral Tregs for Chemotherapy in Patients with Early Breast Cancer
Esther M. de Kruijf; Johanna G.H. van Nes; Anita Sajet; Quirijn R.J.G. Tummers; Hein Putter; Susanne Osanto; Frank M. Speetjens; Vincent T.H.B.M. Smit; Gerrit Jan Liefers; Cornelis J.H. van de Velde; Peter J.K. Kuppen
Chromosome 17 Polysomy without Human Epidermal Growth Factor Receptor 2 Amplification Does Not Predict Response to Lapatinib Plus Paclitaxel Compared with Paclitaxel in Metastatic Breast Cancer
Leona Downey; Robert B. Livingston; Maria Koehler; Michael Arbushites; Lisa Williams; Angela Santiago; Roberta Guzman; Ivonne Villalobos; Angelo Di Leo; Michael F. Press
Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041)
Hanneke W.M. van Laarhoven; Walter Fiedler; Ingrid M.E. Desar; Jack J.A. van Asten; Sandrine Marréaud; Denis Lacombe; Anne-Sophie Govaerts; Jan Bogaerts; Peter Lasch; Johanna N.H. Timmer-Bonte; Antonio Lambiase; Claudio Bordignon; Cornelis J.A. Punt; Arend Heerschap; Carla M.L. van Herpen
Susceptibility and Prevention
Smoking and Colorectal Cancer in Lynch Syndrome: Results from the Colon Cancer Family Registry and The University of Texas M.D. Anderson Cancer Center
Mala Pande; Patrick M. Lynch; John L. Hopper; Mark A. Jenkins; Steve Gallinger; Robert W. Haile; Loic LeMarchand; Noralane M. Lindor; Peter T. Campbell; Polly A. Newcomb; John D. Potter; John A. Baron; Marsha L. Frazier; Christopher I. Amos
Letters to the Editor
Corrections
Highlights
Advertisement
